These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27611858)

  • 1. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes.
    Liao X; Wang X; Li H; Li L; Zhang G; Yang M; Yuan L; Liu H; Yang G; Gao L
    Sci Rep; 2016 Sep; 6():32887. PubMed ID: 27611858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sitagliptin on circulating zinc-α2-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial.
    Tian M; Liang Z; Liu R; Li K; Tan X; Luo Y; Yang M; Gu HF; Liu H; Li L; Yang G
    Eur J Endocrinol; 2016 Feb; 174(2):147-55. PubMed ID: 26546612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zinc alpha-2 glycoprotein is overproduced in Cushing's syndrome.
    Escoté X; Aranda GB; Mora M; Casals G; Enseñat J; Vidal O; Esteban Y; Halperin I; Hanzu FA
    Endocrinol Diabetes Nutr; 2017 Jan; 64(1):26-33. PubMed ID: 28440767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating zinc-α2-glycoprotein levels are low in newly diagnosed patients with metabolic syndrome and correlate with adiponectin.
    Lei L; Li K; Li L; Fang X; Zhou T; Zhang C; Luo Y; Liu H; Li X; Zheng H; Zhang L; Yang G; Gao L
    Nutr Metab (Lond); 2017; 14():53. PubMed ID: 28814962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc-α2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes.
    Yang M; Liu R; Li S; Luo Y; Zhang Y; Zhang L; Liu D; Wang Y; Xiong Z; Boden G; Chen S; Li L; Yang G
    Diabetes Care; 2013 May; 36(5):1074-82. PubMed ID: 23275352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The natural logarithm of zinc-α2-glycoprotein/HOMA-IR is a better predictor of insulin sensitivity than the product of triglycerides and glucose and the other lipid ratios.
    Qu C; Zhou X; Yang G; Li L; Liu H; Liang Z
    Cytokine; 2016 Mar; 79():96-102. PubMed ID: 26797477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc-α2-Glycoprotein Modulates AKT-Dependent Insulin Signaling in Human Adipocytes by Activation of the PP2A Phosphatase.
    Ceperuelo-Mallafré V; Ejarque M; Duran X; Pachón G; Vázquez-Carballo A; Roche K; Núñez-Roa C; Garrido-Sánchez L; Tinahones FJ; Vendrell J; Fernández-Veledo S
    PLoS One; 2015; 10(6):e0129644. PubMed ID: 26068931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating and adipose tissue gene expression of zinc-alpha2-glycoprotein in obesity: its relationship with adipokine and lipolytic gene markers in subcutaneous and visceral fat.
    Ceperuelo-Mallafré V; Näf S; Escoté X; Caubet E; Gomez JM; Miranda M; Chacon MR; Gonzalez-Clemente JM; Gallart L; Gutierrez C; Vendrell J
    J Clin Endocrinol Metab; 2009 Dec; 94(12):5062-9. PubMed ID: 19846741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs.
    Ceperuelo-Mallafré V; Escoté X; Viladés C; Peraire J; Domingo P; Solano E; Sirvent JJ; Pastor R; Tinahones F; Leal M; Richart C; Vendrell J; Vidal F; ; Alba V; Aguilar A; Auguet T; Chacón MR; López-Dupla M; Megia A; Miranda M; Olona M; Saurí A; Vargas M; Velasco I; Veloso S; Fontanet A; Gutiérrez M; Mateo G; Muñoz J; Sambeat MA
    HIV Med; 2012 May; 13(5):297-303. PubMed ID: 22256965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation analysis of IGF-1, ZAG, nesfatin-1, HbA1c levels, and type 2 diabetes mellitus complicated with hypothyroidism.
    He S; He Y; Jin F; Liu Y
    Medicine (Baltimore); 2021 Apr; 100(15):e25432. PubMed ID: 33847643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans.
    Jia Y; Yuan L; Hu W; Luo Y; Suo L; Yang M; Chen S; Wang Y; Liu H; Yang G; Li L
    J Intern Med; 2014 May; 275(5):522-33. PubMed ID: 24283382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
    Basile JN
    J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma zinc α2-glycoprotein levels are elevated in smokers and correlated with metabolic syndrome.
    Tsai JS; Chen SC; Huang KC; Lue BH; Lee LT; Chiu TY; Chen CY; Guo FR; Chuang LM
    Eur J Clin Invest; 2015 May; 45(5):452-9. PubMed ID: 25708842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican-4 is increased in human subjects with impaired glucose tolerance and decreased in patients with newly diagnosed type 2 diabetes.
    Li K; Xu X; Hu W; Li M; Yang M; Wang Y; Luo Y; Zhang X; Liu H; Li L; Yang G
    Acta Diabetol; 2014 Dec; 51(6):981-90. PubMed ID: 25240528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
    Misra M
    J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
    Opie LH
    Cardiovasc Drugs Ther; 2014 Aug; 28(4):331-4. PubMed ID: 24825435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus.
    Aires I; Calado J
    Curr Opin Investig Drugs; 2010 Oct; 11(10):1182-90. PubMed ID: 20872321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.